Beta-blockers taken as adjunctive therapy for lung cancer appear to increase survival rates and reduce metastases, according to a recent review (Lung Cancer Manag 2024;12[4]:LMT63). However, experts agree there are not enough data to change clinical practice; more robust trials are needed.
“We don’t have the data yet, but I think the idea is very promising,” said Xiuning Le, MD, PhD, a thoracic medical oncologist at The University of Texas MD Anderson Cancer Center, in Houston,